Velocity Clinical Research - Market Research Report
Company Overview
Name
Velocity Clinical Research
Mission
Improve the clinical research process to accelerate the delivery of new therapies and provide exceptional care to our community.
Founded and Founders
No information is available
Key People
- Paul Evans, President and CEO
- Raghu Punnamraju, Chief Technology Officer
- Rachael Buck Ph.D., Head of U.K.
- Mike Zaranek, Chief Financial Officer
Headquarters
300 E. Main St., Suite 300, Durham, NC 27701
Number of Employees
No information is available
Revenue
No information is available
Known For
Velocity Clinical Research is known for being the world’s leading organization of fully integrated research sites, partnering with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products.
Products
Research Solutions
Velocity offers comprehensive clinical research services including:
- Unified research site operations for Phase 1-4 clinical trials.
- Patient recruitment and retention strategies.
- Technology solutions for managing clinical trial data and processes.
Key Features
- Access to diverse specialty populations through strategic site locations.
- Next-gen technologies and patient engagement capabilities.
- Extensive database with over 1 million patients.
VISION Platform
A technology platform developed by Velocity to revolutionize clinical trial management.
Key Features
- In-app stipend payments for patients.
- Self-screening and self-scheduling of clinical trials.
- Integration with clinical trial sites to streamline operations.
Recent Developments
New Products Launched
Velocity has been instrumental in the research and FDA approval of multiple medical products in 2024, including:
- Ebglyss (lebrikizumab-lbkz): A treatment for moderate to severe atopic dermatitis (eczema) by Eli Lilly.
- mRESVIA: An RSV vaccine by Moderna for seniors.
- Livdelzi (seladelpar): A second-line treatment for primary biliary cholangitis (PBC) by Gilead.
- Capavaxive: A pneumococcal vaccine by Merck.
- Ohtuvayre (ensifentrine): An inhaled treatment for COPD by Verona.
New Features Added
- More than $2 million in patient stipends paid globally through the VISION platform.
- Enhanced patient engagement tools within the VISION app.
New Partnerships
- Rachael Buck Ph.D. appointed as Head of U.K., leading operational sites in the U.K.
- Collaborative research leading to accelerated FDA approval of multiple products.
Contact Information
Address:
Velocity Clinical Research
300 E. Main St., Suite 300
Durham, NC 27701
Phone: (919) 926-1804
Email: info@VelocityClinical.com
Website: [Velocity Clinical Research](https://velocityclinicaltrials.com)
Sponsors and CROs can reach out via Email: feasibility@VelocityClinical.com
For more information and updates, visit Velocity's news section and follow their social media channels on LinkedIn, X (formerly Twitter), Instagram, and Facebook.
